Pharmacyclics, Inc (NASDAQ:PCYC)’s Price Target Increased

923

Dallas, Texas 03/28/2014 (FINANCIALSTRENDS) – Morgan Stanley has assumed coverage on Pharmacyclics, Inc (NASDAQ:PCYC) shares of Pharmacyclics (NASDAQ:PCYC) in a report released on Wednesday, Stock. The firm has assigned an “equal weight” rating and a price target of $120.00 on the stock. Recently, numerous other analysts have commented on the company stock. Analysts at the Roth Capital firm have upped their price target on Pharmacyclics, Inc (NASDAQ:PCYC) shares to $183.00 in the research note on 24 February. Separately, Zacks analysts have reiterated their neutral rating on Pharmacyclics, Inc (NASDAQ:PCYC) shares in the research note on 24 February.

They have now set a price target of $159.00 on the stock. Finally, the analysts at Deutsche Bank have raised their PT on Pharmacyclics, Inc (NASDAQ:PCYC) shares from $170.00 up to $180.00 in the research note on 21 February. They have now set a rating of “buy rating on the company stock. Four research analysts have rated the Pharmacyclics, Inc (NASDAQ:PCYC) stock with a “hold” rating and 8 have given a “buy” rating to the company. Currently, the average rating on Pharmacyclics, Inc (NASDAQ:PCYC) is a “buy” and the average PT is $156.25.

Pharmacyclics (NASDAQ:PCYC) last issued the company’s quarterly-earnings data on 20 February. It reported earnings per share of $0.95 for the quarter, which topped the average analysts’ projections of beating of $0.67 by $0.28. Pharmacyclics, Inc (NASDAQ:PCYC) had revenue of $123.60M for the quarter, in comparison to the average projection of $85.69 million. On an average, analysts project that Pharmacyclics, Inc (NASDAQ:PCYC) will post earnings per share of $0.11 for the current financial year.

Pharmacyclics, Inc (NASDAQ:PCYC) is a clinical stage bio pharmaceutical company that is focused on the development & commercializing of the small-molecule drugs used to treat cancer & immune mediated diseases. Its clinical development & product candidates are the small-molecule enzyme-inhibitors that are designed to target the biochemical pathways that are involved in human diseases.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.